Skip to main
  1. Stocks
  2. Kestra Medical Technologies Inc
  3. Forecast
KMTS

KMTS Stock Forecast & Price Target

KMTS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 17%
Buy 67%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Kestra Medical Techs is attractive fundamentally because it is still in an early commercial ramp yet delivered F1Q27 sales of $31.0M, up 60% y/y and about $2M above consensus, while FY27 revenue guidance was raised to $141M, implying 48% y/y growth. Its gross margin profile is improving quickly, expanding to 56.5% in F1Q27 from 45.7% a year earlier, marking the 11th consecutive quarter of sequential expansion, and management now targets mid-70s gross margins over time as payor mix and revenue-cycle execution improve. The company also has about $320M of liquidity, roughly 15% U.S. market share, and a differentiated ASSURE platform supported by strong clinical data and broadening coverage, which together underpin confidence in sustained share gains and operating leverage.

Bears say

Kestra Medical Techs is challenged by a fundamentally difficult market where WCD success depends on highly subjective patient selection, uncertain mortality benefit, and compliance that must exceed 22 hours per day, making broad adoption inherently uneven. The 2018 VEST trial enrolled 2,348 patients and failed to meet its primary endpoint, with arrhythmic death of 1.6% versus 2.4% in controls, while adherence fell to a median 18.0 hours per day, reinforcing concerns that real-world effectiveness can be limited by wear-time and overuse in low-risk groups. Although Kestra has captured about 12% US share, its ~7.4x forward P/S multiple implies a roughly 120% premium to the aggregate MedTech multiple, leaving the stock vulnerable if execution or adoption slows.

KMTS has been analyzed by 6 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 67% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.

KMTS Analyst Forecast & Price Prediction

Get the latest KMTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KMTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kestra Medical Technologies Inc (KMTS) Forecast

Analysts have given KMTS a Buy based on their latest research and market trends.

According to 6 analysts, KMTS has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kestra Medical Technologies Inc (KMTS)


KMTS Analyst Forecast & Price Prediction

Get the latest KMTS stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KMTS

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KMTS stock data and trends